Home / Deep Research / Chronic Intestinal Pseudoobstruction

Chronic Intestinal Pseudoobstruction

Chronic Intestinal Pseudoobstruction Deep Research Fallback

⚠️ Fallback MONDO:0017574

Chronic Intestinal Pseudoobstruction Deep Research Fallback

Provider Attempts

No deep-research provider was invoked for this root-level entry. The existing subtype dismech entry (FLNA_Intestinal_Pseudoobstruction) has its own -deep-research-falcon.md artifact from prior curation; this root-level record was curated directly from the verified literature already cached in references_cache/ for the FLNA-CIPO subtype, plus the foundational DOI:10.3389/fped.2022.837462 pediatric-CIPO review, plus ORPHA-grounded subtype identifiers for the X-linked and mitochondrial forms.

Integrated Literature Synthesis

Chronic intestinal pseudoobstruction (CIPO) is a rare, severe disorder of gastrointestinal motility in which patients experience episodes that mimic mechanical bowel obstruction in the absence of any physical luminal blockage. The pediatric review DOI:10.3389/fped.2022.837462 ("Pediatric Intestinal Pseudo-Obstruction: Progress and Challenges") frames CIPO as "the most severe form of gastrointestinal dysmotility with significant morbidity and mortality." That review also distinguishes Pediatric Intestinal Pseudo-Obstruction (PIPO) as biologically and clinically distinct from adult CIPO.

Mechanistic heterogeneity. Primary CIPO partitions along three mechanistic axes that this root entry models as separate atomic pathophysiology nodes converging on a shared Intestinal Dysmotility endpoint:

  • Neuropathic (enteric nervous system defects). The flagship example is X-linked FLNA loss-of-function (PMID:17357080, PMID:18854860), curated in the existing FLNA_Intestinal_Pseudoobstruction dismech entry. The truncated filamin A protein fails to support proper enteric neuron development. Other neuropathic mechanisms include enteric ganglionitis and acquired enteric neuropathies.
  • Myopathic (visceral myopathies). Intrinsic smooth-muscle defects produce poorly contractile or acontractile intestinal smooth muscle. No dedicated dismech entry yet for the visceral-myopathy gene set (e.g., ACTG2, MYLK, MYH11, LMOD1) — scoped as follow-up curation.
  • Mitochondrial / MNGIE. Mitochondrial DNA depletion / instability, classically due to biallelic TYMP (thymidine phosphorylase) loss-of-function, causes mitochondrial neurogastrointestinal encephalomyopathy. MONDO:0011283 (mitochondrial DNA depletion syndrome 1) is the canonical MONDO grounding; this root entry lists TYMP under genetic[] so that a future dedicated MNGIE dismech entry has a starting point.

Clinical syndrome. Six core phenotypes are captured (Intestinal pseudo-obstruction HP:0004389, Abdominal distention HP:0003270, Vomiting HP:0002013, Constipation HP:0002019, Feeding difficulties HP:0011968, Failure to thrive HP:0001508). Frequency tags were deliberately omitted from this root entry per the dismech frequency-evidence SOP — the cited literature supports the existence of these features in CIPO but does not provide subtype-pooled quantitative frequencies appropriate for the umbrella entry.

Management. The supportive-care ladder is captured in treatments[]: parenteral nutrition (NCIT:C29484, the mainstay for patients whose motility cannot sustain enteral intake), enteral nutritional support (MAXO:0000088, preferred when tolerated), surgical management (MAXO:0000004), intestinal transplantation (MAXO:0010039, reserved for irreversible intestinal failure with TPN complications), and genetic counseling (MAXO:0000079) for heritable subtypes.

Out of scope for the root entry

  • Subtype-specific molecular detail for X-linked FLNA-CIPO — already curated in FLNA_Intestinal_Pseudoobstruction.
  • MNGIE / mitochondrial DNA depletion mechanisms beyond the TYMP genetic link — scoped as a dedicated dismech entry.
  • Visceral-myopathy gene-level entries (ACTG2, MYLK, MYH11, LMOD1, etc.) — scoped as follow-up.
  • Secondary CIPO (postsurgical, post-infectious, paraneoplastic, systemic-sclerosis-associated, drug-induced) — explicitly excluded from the primary-CIPO categories enumerated here.